Medical Biochemistry Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
Internal Medicine Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
Mol Biol Rep. 2023 Dec;50(12):9793-9803. doi: 10.1007/s11033-023-08846-y. Epub 2023 Oct 13.
Diabetic nephropathy (DN), which is a chronic outcome of diabetes mellitus (DM), usually progresses to end-stage renal disease (ESRD). The DN pathophysiology, nevertheless, is not well-defined. Several miRNAs were reported to be either risk or protective factors in DN.
METHODS, AND RESULTS: The present study sought to inspect the potential diagnostic and prognostic value of hsa-miR-221 in DN. The study included 200 participants divided into four groups: Group 1 (50 patients with DN), Group 2 (50 diabetic patients without nephropathy), Group 3 (50 nondiabetic patients with CKD), and Group 4 (50 healthy subjects as a control group). Patients in groups 1 and 3 were further classified based on the presence of macroalbuminuria and microalbuminuria. Hsa-miR-221 expression was measured by RT- qRT-PCR. DN patients had significantly elevated serum hsa-miR-221 levels than the other groups, while diabetic patients without nephropathy exhibited elevated levels compared to both nondiabetic patients with CKD, and the control group. The DN patients with macroalbuminuria revealed significantly higher mean values of hsa-miR-221 relative to the patients with microalbuminuria. Significant positive associations were observed in the DN group between serum hsa-miR-221 and fasting insulin, fasting glucose, HOMA IR, ACR, and BMI. The ROC curve analysis of serum hsa-miR-221 in the initial diagnosis of DN in DM revealed high specificity and sensitivity.
It is concluded that hsa-miR-221 has the potential to be a useful biomarker for prognostic and diagnostic purposes in DN.
糖尿病肾病（DN）是糖尿病（DM）的一种慢性后果，通常会发展为终末期肾病（ESRD）。然而，DN 的病理生理学尚未得到很好的定义。有报道称，几种 miRNA 是 DN 的风险或保护因素。
本研究旨在检测 hsa-miR-221 在 DN 中的潜在诊断和预后价值。研究纳入了 200 名参与者，分为四组：第 1 组（50 例 DN 患者）、第 2 组（50 例无肾病的糖尿病患者）、第 3 组（50 例非糖尿病慢性肾病患者）和第 4 组（50 例健康对照者）。第 1 组和第 3 组的患者进一步根据是否存在大量白蛋白尿和微量白蛋白尿进行分类。通过 RT-qRT-PCR 检测 hsa-miR-221 的表达。与其他组相比，DN 患者的血清 hsa-miR-221 水平显著升高，而无肾病的糖尿病患者的水平高于非糖尿病慢性肾病患者和对照组。大量白蛋白尿的 DN 患者的 hsa-miR-221 平均值明显高于微量白蛋白尿患者。DN 组中，血清 hsa-miR-221 与空腹胰岛素、空腹血糖、HOMA-IR、ACR 和 BMI 之间存在显著正相关。在 DM 患者中，血清 hsa-miR-221 对 DN 的初始诊断具有较高的特异性和敏感性。
hsa-miR-221 有望成为 DN 预后和诊断的有用生物标志物。
